Print
Advertisement
Samir Parekh, MD, Appointed Director of the Center of Excellence for Multiple Myeloma at Mount Sinai
Dr. Parekh’s laboratory focuses on developing personalized treatment strategies for patients with multiple myeloma.
Douglas Graham, MD, PhD, a hematologist-oncologist specializing in pediatric leukemia, was recognized in Atlanta Magazine.
Tycel Phillips, MD, discussed his presentation on BTK inhibitors from the International Ultmann Chicago Lymphoma Symposium.
The award provides early-career researchers at NCCN Member Institutions with $150,000 in funding to support cancer research.
Nirav Shah, MD, MSHP, recently presented at the International Ultmann Chicago Lymphoma Symposium on this subject.
Joseph G. Jurcic, MD on the journey to survivorship for adults with either AML or ALL.
Advertisement
Dr. Richard shares her passion for cellular therapy, how her mother’s leukemia diagnosis shaped her career, and more.
Readmission rates were higher among patients with AML with high incomes compared with patients with low incomes.
The award recognizes physician-scientists who made notable research achievements early in their first faculty appointment.
The FDA approvals of CAR T-cell therapies have changed the treatment landscape for several hematologic malignancies.
Dr. Gerds describes his journey to becoming a hematologist oncologist at the Cleveland Clinic.
Scientific evidence indicates that CAR-T can be safely administered on an outpatient basis at specialized medical centers.
Several hematologists were recognized for their contributions to the fields of HSCT and cellular therapy.
Patient-reported response is associated with overall response, total symptom score response, and failure-free survival.
Dr. Cole spoke about becoming an oncologist, his commitment to mitigating disparities for Black patients with MM, and more.
Blood Cancers Today spoke with several clinicians about how quadruplets are changing the myeloma treatment landscape.
The approval is based on results of the FELIX trial, which evaluated the safety and efficacy of obe-cel.
The approval is based on results of the phase I/II AUGMENT-101 trial, where revumenib achieved a CR+CRh rate of 21%.
The interest in using quantitative tests to measure residual cancer cells continues to expand in the arena of blood cancers.
Since 1974, Dr. Steven Rosenberg has served as Chief of the Surgery Branch at the NCI.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.